Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EX Other protein kinase inhibitors L01EX09 Nintedanib D10396 Nintedanib esylate (USAN) <JP/US> USP drug classification [BR:br08302] Respiratory Tract/Pulmonary Agents Pulmonary Fibrosis Agents Nintedanib D10396 Nintedanib esylate (USAN) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 39 Other agents affecting metabolism 399 Miscellaneous 3999 Others D10396 Nintedanib esylate (USAN); Nintedanib ethanesulfonate (JAN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01374 Nintedanib D10396 Nintedanib esylate Metabolizing enzyme substrate DG02924 UGT substrate DG01374 Nintedanib D10396 Nintedanib esylate Transporter substrate DG01665 ABCB1 substrate DG01374 Nintedanib D10396 Nintedanib esylate Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) PDGFR family PDGFR D10396 Nintedanib esylate (USAN) <JP/US> FGFR family FGFR1 (CD331) D10396 Nintedanib esylate (USAN) <JP/US> FGFR2 (CD332) D10396 Nintedanib esylate (USAN) <JP/US> FGFR3 (CD333) D10396 Nintedanib esylate (USAN) <JP/US> VEGFR family VEGFR1 (FLT1) D10396 Nintedanib esylate (USAN) <JP/US> VEGFR2 (KDR) D10396 Nintedanib esylate (USAN) <JP/US> VEGFR3 (FLT4) D10396 Nintedanib esylate (USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10396 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10396 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10396 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10396 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10396 Drug transporters D10396 Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01374 Nintedanib Metabolizing enzyme substrate DG02924 UGT substrate DG01374 Nintedanib Transporter substrate DG01665 ABCB1 substrate DG01374 Nintedanib
Other DBs
KCF data
ATOM 46 1 S4a S 30.0803 -11.0132 2 O1d O 30.0803 -9.6159 3 O1d O 30.0803 -12.4804 4 C1b C 28.6830 -11.0132 5 O1d O 31.4776 -11.0132 6 C1a C 27.9843 -9.8031 7 C5a C 19.1800 -10.4300 8 N1c N 17.9900 -9.7300 9 C8y C 16.8000 -10.4300 10 C8x C 15.5400 -9.7300 11 C8y C 14.3500 -10.4300 12 C8x C 14.3500 -11.8300 13 C8x C 15.5400 -12.5300 14 C8x C 16.8000 -11.8300 15 N1b N 13.1600 -9.8000 16 O5a O 19.1800 -11.8300 17 N1y N 21.4200 -10.2200 18 C1x C 21.4200 -11.6200 19 C1x C 22.6100 -12.3200 20 N1y N 23.8000 -11.6200 21 C1x C 23.8000 -10.2200 22 C1x C 22.6100 -9.5200 23 C1a C 25.0600 -12.3200 24 C1b C 20.1600 -9.5900 25 C1a C 17.9900 -8.4000 26 C2c C 12.0400 -10.5700 27 C2y C 10.7800 -9.9400 28 C8y C 12.0400 -11.9700 29 C8x C 10.8500 -12.6700 30 C8x C 10.8500 -14.0700 31 C8x C 12.0400 -14.7700 32 C8x C 13.3000 -14.0700 33 C8x C 13.3000 -12.6700 34 C5x C 10.5700 -8.5400 35 N1x N 9.1700 -8.2600 36 C8y C 8.4700 -9.5200 37 C8y C 9.4500 -10.5700 38 O5x O 11.5500 -7.5600 39 C8x C 7.1400 -9.8700 40 C8y C 6.7200 -11.2000 41 C8x C 7.7000 -12.2500 42 C8x C 9.1000 -11.9000 43 O7a O 4.3400 -11.2000 44 C7a C 5.5300 -11.9000 45 O6a O 5.5300 -13.3000 46 C1a C 3.1500 -11.9000 BOND 49 1 1 2 2 2 1 3 2 3 1 4 1 4 1 5 1 5 4 6 1 6 9 10 2 7 10 11 1 8 11 12 2 9 12 13 1 10 13 14 2 11 14 9 1 12 11 15 1 13 7 16 2 14 7 8 1 15 8 9 1 16 17 18 1 17 18 19 1 18 19 20 1 19 20 21 1 20 21 22 1 21 22 17 1 22 20 23 1 23 17 24 1 24 7 24 1 25 8 25 1 26 15 26 1 27 26 27 2 28 26 28 1 29 28 29 2 30 29 30 1 31 30 31 2 32 31 32 1 33 32 33 2 34 28 33 1 35 27 34 1 36 34 35 1 37 35 36 1 38 36 37 1 39 27 37 1 40 34 38 2 41 36 39 2 42 39 40 1 43 40 41 2 44 41 42 1 45 37 42 2 46 43 44 1 47 44 40 1 48 44 45 2 49 43 46 1
